3 completed, 2 unknown, 1 not yet recruiting, 1 recruiting. 4 Phase 2, 2 Not applicable, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Not yet recruiting 1, Recruiting 1, Terminated 1, Unknown 1 |
| Not applicable | 2 | Completed 1, Unknown 1 |
| Phase 1 | 2 | Completed 2 |
Follow Sinew Pharma Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis SNP-610, Placebo Oral Tablet - NASH - Nonalcoholic Steatohepatitis | Phase 2 | Not yet recruiting | Sinew Pharma Inc. | 80 | 2026-04-01 | 2026-03-18 |
| A Novel, Potent and Non-addictive Analgesic of Combinations for Knee Replacement Moderate to Severe Pain Management Naldebain, SafeTynadol, Naldebain + SafeTynadol - Pain, Postoperative | Phase 2 | Unknown | Sinew Pharma Inc. | 36 | 2023-07-25 | 2023-07-27 |
| To Evaluate the Efficacy and Safety of TYNADOTE® in the Treatment of Acetaminophen Overdose TYNADOTE, Placebo Oral Tablet - Hepatitis | Phase 2 | Recruiting | Sinew Pharma Inc. | 24 | 2023-05-01 | 2024-01-10 |
| A Partial Randomized, Single-blind or Open-label, Dose-escalation With Multiple-dose Design Study to Evaluate the Pharmacokinetics of Acetaminophen and Its Toxic Metabolites With Panadol® and SafeTynadol® in Healthy Volunteers Panadol®, SafeTynadol® - Hepatitis, Pharmacology | Not applicable | Unknown | Sinew Pharma Inc. | 48 | 2022-10-28 | 2024-03-27 |
| A Randomized, Single-blind, Parallel Group and Multiple - Dose Design Study Panadol®, SafeTynadol® - Acetaminophen Toxicity | Not applicable | Completed | Sinew Pharma Inc. | 28 | 2022-05-19 | 2023-07-18 |
| A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of SNP-630 in Health Subjects. SNP-630 - NASH - Nonalcoholic Steatohepatitis | Phase 1 | Completed | Sinew Pharma Inc. | 28 | 2021-07-22 | 2021-10-11 |
| An Open-Label Study to Assess the Hepatic Protection Effect of SNP-612, in Patients With NAFLD SNP-612 dose1, SNP-612 dose2 - NASH - Nonalcoholic Steatohepatitis | Phase 2 | Terminated | Sinew Pharma Inc. | 90 | 2017-08-04 | 2023-01-06 |
| Phase I Pharmacokinetic Study of HUYPS-1 in Healthy Volunteers HUYPS-1 one tablet, HUYPS-1 nine tablets - Nonalcoholic Steatohepatitis | Phase 1 | Completed | Sinew Pharma Inc. | 14 | 2016-05-10 | 2023-08-09 |
Non-alcoholic Fatty Liver Disease (4) · Liver Failure, Acute (3) · Hepatitis (2) · Pain, Postoperative (1)
Acetaminophen (2) · Polyethylene Glycols (1)
Taiwan (7)
Cheng-Fong Mr Chen, PhD (1) · TeYu Mr Lin, Dr. (1) · Yu-Lueng Shih, MD,PhD (1)